Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Plos One|September 4, 2024
Prediction of infectious diseases using sentiment analysis on social media dataYoungchul Song, Byungun YoonFoods (Basel, Switzerland)|January 8, 2025
Integrated Quality Prediction Model for Food Quality Management Based on E. coli in Shared KitchensTaeyeoun Roh, Youngchul Song, Byungun YoonCancer Research|April 20, 2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionRyohei Katayama, Aki Aoyama, Takao Yamori, et al.Cancer Research|May 4, 2012
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsAlexa B Turke, Youngchul Song, Carlotta Costa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2Brent N Rexer, Ritwik Ghosh, Archana Narasanna, et al.Oncotarget|July 25, 2018
RET fusions observed in lung and colorectal cancers are sensitive to ponatinibJoseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, et al.The Journal of Clinical Investigation|June 24, 2008
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsMarta Guix, Anthony C Faber, Shizhen Emily Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.Pageof 3